Quick Stack Summary
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Role in the stack | GHRH receptor signal | Ghrelin receptor signal |
| Typical research dose | 100-300mcg per injection | 200-300mcg per injection |
| With DAC frequency | 1-2x per week (DAC form only) | N/A |
| Without DAC frequency | Daily, similar pattern to Ipamorelin | Typically 1-3x daily |
| Shared marker to track | IGF-1 | |
Why These Two Are Often Combined
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), acting on the GHRH receptor. Ipamorelin is a selective ghrelin receptor agonist, acting on a different receptor entirely. Because both pathways converge on the same pituitary cells and the same outcome, a pulse of growth hormone release, but arrive there through separate signals, combining them is one of the most common pairings in the growth-hormone peptide space. For a deeper look at the mechanism difference itself, see CJC-1295 vs Ipamorelin.
Complementary, not redundant: the rationale for stacking these two rests on them acting through different receptors rather than the same one. That's a mechanistically defensible reason to combine them. It is not the same as saying a controlled trial has measured the combined effect and found it exceeds either compound alone; no such trial exists for this specific pairing.
CJC-1295's Role: With DAC vs Without DAC
CJC-1295 comes in two forms that behave differently in a stack. With DAC (Drug Affinity Complex), it binds serum albumin and has an extended half-life of several days, allowing infrequent dosing, roughly once or twice a week. Without DAC, also called Mod GRF 1-29, it has a short half-life of about 30 minutes and is dosed more frequently, similar in pattern to Ipamorelin. Which form is used changes how the whole stack is timed, so it's worth knowing which one is actually in a given product before planning a schedule.
Timing and Sequencing
A commonly discussed pattern in the peptide research community is dosing on an empty stomach, roughly 20 to 30 minutes before eating, often before bed and around fasted training. The general physiological basis for this is that growth hormone secretion is naturally more active during sleep and can be blunted by elevated blood glucose and insulin, so dosing when both are low is thought to give the pulse a clearer path. This is a widely discussed pattern rather than a finding from a study of this specific stack, and individual protocols vary.
Safety Considerations
Both compounds are sold as research chemicals, not FDA-approved drugs, and neither has the kind of large-scale human safety data an approved medication would have. Combining two compounds means combining whatever individual safety unknowns each one carries, not just their intended effects. For a closer look at what's actually been shown for each compound in humans versus animals, see the evidence reviews for CJC-1295 and Ipamorelin.
Bloodwork to Track
IGF-1 is the standard marker for tracking growth-hormone-axis activity with this stack, since growth hormone itself is released in short pulses that are hard to catch on a single blood draw. A baseline IGF-1 test before starting, and a follow-up around 8 to 12 weeks in, is the most direct way to see whether the stack is doing what it's intended to do. See the full peptide bloodwork guide for the rest of a baseline panel.
Related Reading
For the mechanism comparison behind this stack, see CJC-1295 vs Ipamorelin. For the alternative pairing with Sermorelin instead of CJC-1295, see Ipamorelin vs Sermorelin. For guidance on how many compounds to run at once and how to avoid overlap in a stack, see How Many Peptides Should Be in a Stack? and What Does "Synergy" Actually Mean?. BioStackIQ's Rate My Stack and Build Protocol can help plan dosing and timing once a direction is chosen.